{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2024"],"data_sharing_plan":["IPD Sharing (as of July 2023): No"],"condition":["Metastatic Colorectal Cancer","Neoplasm Metastasis","Metastatic Gastric Cancer","Metastatic Breast Cancer","Metastatic Pancreatic Cancer","Metastatic Urothelial Carcinoma","Solid tumors","Metastatic Cancer"],"disease":["Metastatic Colorectal Cancer","Neoplasm Metastasis","Metastatic Gastric Cancer","Metastatic Breast Cancer","Metastatic Pancreatic Cancer","Metastatic Urothelial Carcinoma","Metastatic Cancer","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/66159"],"study_start_month":["1"],"keyword":["CCR5"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of OB-002 in Patients With Refractory Metastatic Cancer","description":"This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.","dates":{"creation":"2024-01-15"},"accession":"66159","cross_references":{"ClinicalTrials___gov":["NCT05940844"]}}